<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H87AB370D96374E919A7DD6B33F49C6D7" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 2031 IH: Trial and Experimental Studies Transparency Act of 2012</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-05-16</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2031</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130516">May 16, 2013</action-date>
			<action-desc><sponsor name-id="M000133">Mr. Markey</sponsor> (for
			 himself, <cosponsor name-id="W000215">Mr. Waxman</cosponsor>,
			 <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, and
			 <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title IV of the Public Health Service Act to
		  expand the clinical trial registry data bank, and for other
		  purposes.</official-title>
	</form>
	<legis-body id="H7813A0F9F19D49C5AAC368F6F1D9C918" style="OLC">
		<section id="H2A8D167A6F07478D90627903DA5AA22B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Trial and Experimental Studies
			 Transparency Act of 2012</short-title></quote> or the <quote><short-title>TEST Act</short-title></quote>.</text>
		</section><section id="H98F9056ECB0A45C79BD4593F6395D0C5" section-type="subsequent-section"><enum>2.</enum><header>Expanded clinical
			 trial registry data bank</header>
			<subsection id="H6DDFBD59734741DCB6FFA08A393E9E9A"><enum>(a)</enum><header>In
			 general</header><text display-inline="yes-display-inline">Section 402(j) of the
			 Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>) is amended—</text>
				<paragraph id="HC4807FC04EB744C287FD08011C829FB1"><enum>(1)</enum><text>in paragraph
			 (1)(A)—</text>
					<subparagraph id="H3F7731B2806148538F9071DD50CFAEDD"><enum>(A)</enum><text display-inline="yes-display-inline">in clause (ii)—</text>
						<clause id="HFD1CB2F1B7734B1A9BE6788149AE8F6F"><enum>(i)</enum><text>by
			 amending subclause (I) to read as follows:</text>
							<quoted-block display-inline="no-display-inline" id="H823D1FF78B854D24ACC7882595778762" style="OLC">
								<subclause id="HD2C75D0CC79E4EA2851EA6A12F030593"><enum>(I)</enum><text display-inline="yes-display-inline">an interventional study of a device subject
				to section 510(k), 515, or 520(m) of the Federal Food, Drug, and Cosmetic Act,
				including any interventional study of a device conducted outside of the United
				States the results of which are submitted to the Secretary in support of a PMA
				(as such term is defined in <external-xref legal-doc="usc" parsable-cite="usc/21/814">section 814.3(e)</external-xref> of title 21, Code of Federal
				Regulations); a premarket notification required under section 510(k) of the
				Federal Food, Drug, and Cosmetic Act; or a HDE (as such term is defined in
				<external-xref legal-doc="usc" parsable-cite="usc/21/814">section 814.3(m)</external-xref> of title 21, Code of Federal
				Regulations).</text>
								</subclause><after-quoted-block>;
				and</after-quoted-block></quoted-block>
						</clause><clause id="HF9F8ABD4057640C5AEB3E90520E82384"><enum>(ii)</enum><text>in
			 subclause (II)—</text>
							<subclause id="H7E1539313EE4473A8382F93CEB7A6A9D"><enum>(I)</enum><text>by striking
			 <quote>pediatric</quote>; and</text>
							</subclause><subclause id="H957F7AA68EFB4DA286CDC3F1651853EC"><enum>(II)</enum><text>by inserting
			 <quote>that involves data collection from human subjects</quote> before the
			 period at the end;</text>
							</subclause></clause></subparagraph><subparagraph id="HA1639D49FE754DF09F5D5418ACB4DA0C"><enum>(B)</enum><text>by amending clause
			 (iii) to read as follows:</text>
						<quoted-block display-inline="no-display-inline" id="H85EE2E458C53422C9A97772431B9C8AC" style="OLC">
							<clause id="H524506D30E7640118799E39563B3BFAC"><enum>(iii)</enum><header>Applicable
				drug clinical trial</header><text display-inline="yes-display-inline">The term
				<term>applicable drug clinical trial</term> means an interventional study of a
				drug subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to
				section 351 of this Act, including any interventional study of a drug conducted
				outside of the United States the results of which are submitted to the
				Secretary in support of—</text>
								<subclause id="HA3C6320D2CD44746A2333687FF858693"><enum>(I)</enum><text>an IND (as such
				term is defined in <external-xref legal-doc="usc" parsable-cite="usc/21/312">section 312.3</external-xref> of title 21, Code of Federal
				Regulations);</text>
								</subclause><subclause id="HF6ECABB36DB5413DA326BE47A5F9CAA6"><enum>(II)</enum><text>an application
				filed under subsection (b) or (j) of such section 505 of the Federal Food,
				Drug, and Cosmetic Act; or</text>
								</subclause><subclause id="H5CAAFC85B34C4E50A7DD83C47DE6DAF0"><enum>(III)</enum><text>an application
				for a license under section
				351.</text>
								</subclause></clause><after-quoted-block>;</after-quoted-block></quoted-block>
					</subparagraph><subparagraph id="HBAB1E74A9CDC42ABBB08277326643281"><enum>(C)</enum><text>by redesignating
			 clauses (iv) through (ix) as clauses (v) through (x), respectively;</text>
					</subparagraph><subparagraph id="HAF17CF08723A4FFAAC092A0118B117AC"><enum>(D)</enum><text>after clause
			 (iii), by inserting the following new clause:</text>
						<quoted-block display-inline="no-display-inline" id="H460E4A768E54463AB21B12FE8B6A3A92" style="OLC">
							<clause id="H40A5577D30AE487BA12021BA64777005"><enum>(iv)</enum><header>Interventional
				study</header><text display-inline="yes-display-inline">For purposes of clauses
				(ii) and (iii), the term <term>interventional study</term> means a study in
				human beings in which individuals are assigned by an investigator, based on a
				protocol, to receive specific interventions to evaluate their effects on
				biomedical or health-related outcomes.</text>
							</clause><after-quoted-block>;
				and</after-quoted-block></quoted-block>
					</subparagraph><subparagraph id="H08B81203EBDD40FF8FF9384B176F9A84"><enum>(E)</enum><text>in clause (vi), as
			 redesignated by
			 <internal-xref idref="HBAB1E74A9CDC42ABBB08277326643281" legis-path="2.(a)(1)(C)">subparagraph (C)</internal-xref>—</text>
						<clause id="H5BC9ABB8C1FE4F6CB3DE2C9CE7CE6D0E"><enum>(i)</enum><text>in
			 the heading, by inserting <quote><header-in-text level="clause" style="OLC">;
			 primary completion date</header-in-text></quote> after <quote><header-in-text level="clause" style="OLC">date</header-in-text></quote>; and</text>
						</clause><clause id="H296DCFB267CC4B3EBE16AA3379E30BAA"><enum>(ii)</enum><text display-inline="yes-display-inline">by inserting <quote>, also referred to as
			 <quote>primary completion date</quote>,</quote> before
			 <quote>means</quote>;</text>
						</clause></subparagraph></paragraph><paragraph id="HDB4B9B8281B247FFA50BE9B5489D4577"><enum>(2)</enum><text>in paragraph
			 (2)—</text>
					<subparagraph id="HD362322914E34458A412A7B8E17DBFE0"><enum>(A)</enum><text>in subparagraph
			 (A)(ii)—</text>
						<clause id="H161A250352364A83AB3DBA51DED229A7"><enum>(i)</enum><text>by
			 redesignating subclauses (II), (III), and (IV) as subclauses (III), (IV), and
			 (V), respectively;</text>
						</clause><clause id="H22856387798C474D9E6B0E9D2CE48E40"><enum>(ii)</enum><text>by
			 inserting after subclause (I) the following:</text>
							<quoted-block display-inline="no-display-inline" id="HE3F02E3743C94E25A7A5911F86A5CE68" style="OLC">
								<subclause id="HA91BA139FF724031B5F41DB4B9989C2F"><enum>(II)</enum><text display-inline="yes-display-inline">supporting documents, including—</text>
									<item id="HF1B2E6C9A28144A6BB7755A6B94D2B24"><enum>(aa)</enum><text>consent documents
				used to enroll subjects into the trial, as approved by the Institutional Review
				Board or equivalent committee prior to the start of the trial; and</text>
									</item><item id="H14BB3F7B9D124BFE89093D552853CA1B"><enum>(bb)</enum><text>protocol
				documents, as approved by the Institutional Review Board or equivalent
				committee prior to the start of the
				trial;</text>
									</item></subclause><after-quoted-block>;
				and</after-quoted-block></quoted-block>
						</clause><clause id="H65FD4C554DEB48239704AEAE34227F78"><enum>(iii)</enum><text>in
			 subclause (IV), as so redesignated, in item (cc), by inserting <quote>(or, in
			 the case of a location outside of the United States, other appropriate location
			 information)</quote> after <quote>zip code</quote>;</text>
						</clause></subparagraph><subparagraph id="H5FF14D234E5A4D7F9170D99D1268D055"><enum>(B)</enum><text>in subparagraph
			 (C)(ii) by striking <quote>21 days after</quote> and inserting
			 <quote>before</quote>; and</text>
					</subparagraph><subparagraph id="HA6C396BE991446309F5315DF619899C8"><enum>(C)</enum><text>by amending
			 subparagraph (D) to read as follows:</text>
						<quoted-block display-inline="no-display-inline" id="HD6C26FD591FC4D39BE05DDB56C7DEAF3" style="OLC">
							<subparagraph id="HB0C92E41CC15460CB8625E8DFAAC102D"><enum>(D)</enum><header>Posting of
				Data</header><text display-inline="yes-display-inline">The Director of NIH
				shall ensure that clinical trial information for an applicable clinical trial
				submitted in accordance with this paragraph is posted publically in the
				registry data bank not later than 30 days after such submission is determined
				to meet the quality criteria established by the Director of
				NIH.</text>
							</subparagraph><after-quoted-block>; </after-quoted-block></quoted-block>
					</subparagraph></paragraph><paragraph id="H7CA05810A4764F66AB5040F76B5A5C3E"><enum>(3)</enum><text>in paragraph
			 (3)—</text>
					<subparagraph commented="no" id="H4498909DEFAF473889C4AD1A88BB2B55"><enum>(A)</enum><text>in subparagraph
			 (C)—</text>
						<clause commented="no" id="H3FF563CB96BD4FF4B8F454FCEE96AE79"><enum>(i)</enum><text>by striking
			 <quote>Not later than 1 year</quote> and all that follows through the colon and
			 inserting <quote>Subject to subparagraph (2)(C), the Secretary shall include in
			 the registry and results data bank the following elements for an applicable
			 clinical trial:</quote>; and</text>
						</clause><clause id="H97BD237A003C4B28BE3ECAEADDAC3D91"><enum>(ii)</enum><text>by
			 adding at the end the following new clause:</text>
							<quoted-block display-inline="no-display-inline" id="H2704A0DCA75A40C685FEE31480A5C9E4" style="OLC">
								<clause id="HEF5DE3371A1E46C1BB9F95FB323E7383"><enum>(v)</enum><header>Supporting
				documents</header><text display-inline="yes-display-inline">Final consent and
				protocol documents, including all dated amendments to the initial version of
				such documents, as approved by the Institutional Review Board or equivalent
				committee.</text>
								</clause><after-quoted-block>;</after-quoted-block></quoted-block>
						</clause></subparagraph><subparagraph id="H80277752782B48798E628CED595CBBF7"><enum>(B)</enum><text>in subparagraph
			 (D)—</text>
						<clause id="H6BB12580145D48BD9C2C62D5995F4B5C"><enum>(i)</enum><text>by
			 striking clauses (ii) and (iv);</text>
						</clause><clause id="HCC9AA1B224D14972ABB7CE335547F0D3"><enum>(ii)</enum><text>in
			 clause (iii)—</text>
							<subclause id="HD673E6B8F04E4A1289B09A16BE8BB1D1"><enum>(I)</enum><text>by striking
			 subclause (III); and</text>
							</subclause><subclause id="H9BE77CDC61154D688180F5B8119FBF0A"><enum>(II)</enum><text>by redesignating
			 subclause (IV) as subclause (III); and</text>
							</subclause></clause><clause id="HDD223849C7CF4208B2603D31FE894898"><enum>(iii)</enum><text>by
			 redesignating—</text>
							<subclause id="HF4470CA94B464C3EB19A82A78F50D978"><enum>(I)</enum><text>clause (iii) as
			 clause (ii); and</text>
							</subclause><subclause id="H316F07D80FC14B5BBE921361F0B7625C"><enum>(II)</enum><text>clauses (v)
			 through (vii) as clauses (iii) through (v), respectively;</text>
							</subclause></clause></subparagraph><subparagraph id="H3183A7AC2599482FA0DC55724AD4AFCF"><enum>(C)</enum><text>in subparagraph
			 (E)—</text>
						<clause id="H34B8A3B89E1341DD8D05B134C6DC2BBA"><enum>(i)</enum><text>by
			 striking clauses (i) through (v) and inserting the following:</text>
							<quoted-block display-inline="no-display-inline" id="H580A534078C44093ADCBAA12D30DDB75" style="OLC">
								<clause id="H3DF40B344C5A407A946A70CED8099A9F"><enum>(i)</enum><header>In
				general</header><text>Except as provided in clauses (ii) and (iii), the
				responsible party for an applicable clinical trial shall submit to the Director
				of NIH for inclusion in the registry and results data bank the clinical trial
				information described in subparagraph (C) not later than 1 year after the
				primary completion date of such trial.</text>
								</clause><clause id="HC239EFF8E0D946318934536B4765301C"><enum>(ii)</enum><header>Delayed
				submission of results with certification</header><text>If the responsible party
				for an applicable clinical trial submits a certification that an applicable
				clinical trial involves a drug described in clause (iii) or a device described
				in clause (iv), the responsible party shall submit to the Director of NIH, for
				inclusion in the registry and results data bank, the clinical trial information
				described in subparagraphs (C) and (D) not later than the earliest of the
				following:</text>
									<subclause display-inline="no-display-inline" id="HEB7FB8A9640B42469AD0825B42367BFE"><enum>(I)</enum><text>The later
				of—</text>
										<item id="H746565B71C28401EAD714E5B95F39278"><enum>(aa)</enum><text>30
				days after the drug or device is approved, licensed, or cleared, as applicable;
				or</text>
										</item><item id="H7C03D0854F824BFAA168F66C7B9E13B8"><enum>(bb)</enum><text>1
				year after the primary completion date of the applicable clinical trial.</text>
										</item></subclause><subclause id="HA8DEC941C23E42179FCF0E95D7D7CA85"><enum>(II)</enum><text>The date that is
				2 years after the primary completion date of the applicable clinical
				trial.</text>
									</subclause></clause><clause id="H01F8BFE724934C228238D62533A7F924"><enum>(iii)</enum><header>Drug
				described</header><text>A drug described in this clause is a drug that contains
				an active ingredient, including any ester or salt, that has not been an
				ingredient in a drug approved in any other application under section 505 of the
				Federal Food, Drug, and Cosmetic Act or licensed for any use under section 351
				of this Act.</text>
								</clause><clause id="HEE556896305843B4AFB91874B5F20A1B"><enum>(iv)</enum><header>Device
				described</header><text>A device described in this clause is a device that has
				not been approved or cleared for any use under section 510(k) or under section
				515 or 520(m) of the Federal Food, Drug, and Cosmetic
				Act.</text>
								</clause><after-quoted-block>; </after-quoted-block></quoted-block>
						</clause><clause id="HB58728DD505248CBA7489C1D3164DC1E"><enum>(ii)</enum><text display-inline="yes-display-inline">by redesignating clause (vi) as clause (v);
			 and</text>
						</clause><clause id="HF03B2092A045414AB08AC45C4AD34241"><enum>(iii)</enum><text>by
			 adding at the end the following:</text>
							<quoted-block display-inline="no-display-inline" id="HA2F413754C8A4AC2B430B607BC070F4C" style="OLC">
								<clause id="HCD294EF4A30B498C98987F5E914ECA85"><enum>(vi)</enum><header>Public postings
				related to delays and extensions</header><text display-inline="yes-display-inline">Information submitted by the responsible
				party as part of a certification for delayed submission of results submitted
				under clause (ii) or a request for extension submitted under clause (v) shall
				be posted publically in the registry data
				bank.</text>
								</clause><after-quoted-block>; </after-quoted-block></quoted-block>
						</clause></subparagraph><subparagraph id="HF2EC2A20E2E04C4384D9CBDC13AA2AC2"><enum>(D)</enum><text>by striking
			 subparagraph (F);</text>
					</subparagraph><subparagraph id="H53BD29E9C6F64FA9BEF9565515ED7CDA"><enum>(E)</enum><text>by redesignating
			 subparagraphs (G) through (I) as subparagraphs (F) through (H), respectively;
			 and</text>
					</subparagraph><subparagraph id="H33C4B8A82B484D3CB9DB2294952AAC37"><enum>(F)</enum><text>in subparagraph
			 (F), as so redesignated, by inserting before the period at the end the
			 following: <quote>is determined to meet the quality criteria established by the
			 Director of NIH</quote>; and</text>
					</subparagraph></paragraph><paragraph id="HC359D69B87A1409E8871CC0D0FAF7A9C"><enum>(4)</enum><text>in paragraph
			 (4)(B)—</text>
					<subparagraph display-inline="no-display-inline" id="H1FBD11FD3F2F496E96CDE58971BBE678"><enum>(A)</enum><text>in clause (i)(II),
			 by striking <quote>(3)(E)(iii)</quote> and inserting <quote>(3)(E)(ii)</quote>;
			 and</text>
					</subparagraph><subparagraph id="HE2EEA69DB90045F2A4C9337B9B353305"><enum>(B)</enum><text display-inline="yes-display-inline">in clause (ii)(II)—</text>
						<clause id="HE10E5FA462914550B5F5F036531073BF"><enum>(i)</enum><text>by
			 striking <quote>by both</quote>; and</text>
						</clause><clause id="HC2CA15A8B96842EDA8F6DA2C34C11CB9"><enum>(ii)</enum><text>by
			 striking <quote>and paragraph (3)(D)(ii)(II))</quote>.</text>
						</clause></subparagraph></paragraph></subsection><subsection id="HE2DD4D0835C04864B869B8FC2720A46B"><enum>(b)</enum><header>Implementation</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services
			 shall implement the amendments made by subsection (a) not later than 6 months
			 after the date of enactment of this Act.</text>
			</subsection></section><section commented="no" id="H1C944E96553448038DC1A05BE8F8DD38"><enum>3.</enum><header>Reporting
			 requirement</header><text display-inline="no-display-inline">Not later than 2
			 years after the date of the enactment of this Act, and annually thereafter, the
			 Director of the National Institutes of Health and the Commissioner of the Food
			 and Drug Administration shall each submit to the Committee on Energy and
			 Commerce of the House of Representatives and the Committee on Health,
			 Education, Labor, and Pensions of the Senate a report that includes the
			 following:</text>
			<paragraph commented="no" id="HF31D64EA64B94320812EC731ACA666B6"><enum>(1)</enum><text>Based on
			 information that is readily available in the data bank described in section
			 402(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>)—</text>
				<subparagraph commented="no" id="H8755FC73D3434EBF978E457981B1EE1D"><enum>(A)</enum><text>the number of
			 trials that the Director or Commissioner, as applicable, has identified as
			 trials that are likely to be subject to the reporting requirements of such
			 section;</text>
				</subparagraph><subparagraph commented="no" id="HD43279129EDF41D0A6E383F5285CE80F"><enum>(B)</enum><text display-inline="yes-display-inline">of the trials identified under
			 <internal-xref idref="H8755FC73D3434EBF978E457981B1EE1D" legis-path="3.(1)(A)">subparagraph (A)</internal-xref>, the estimated numbers
			 and percentages of such trials—</text>
					<clause id="HE10F1C64BDB3432B9C186CF8BEB95FDC"><enum>(i)</enum><text>that
			 have complete registration information; and</text>
					</clause><clause id="HEBAFD0FE916B4EBDB1CD5C4845F85951"><enum>(ii)</enum><text>that have met the
			 result reporting requirements of section 402(j) of the Public Health Service
			 Act; and</text>
					</clause></subparagraph><subparagraph commented="no" id="H8AA5154F13924AA786C2D2E4D421309B"><enum>(C)</enum><text display-inline="yes-display-inline">whether results of the trials have been
			 submitted by the responsible party by the due dates outlined in section 402(j)
			 of the Public Health Service Act and, if not, whether certifications for
			 delayed submission of such results, or requests for extensions, have been
			 submitted by the responsible party.</text>
				</subparagraph><continuation-text continuation-text-level="paragraph">For purposes
			 of this paragraph, the Secretary may use an algorithm or other technique for
			 efficiently reviewing large amounts of data.</continuation-text></paragraph><paragraph id="H823EB998139B473B96CD0778DFD06869"><enum>(2)</enum><text display-inline="yes-display-inline">A description of any actions taken to
			 consult with other Federal agencies under 402(j)(5)(A)(iv) of the Public Health
			 Service Act.</text>
			</paragraph><paragraph id="H70FA824A19664B2188B728B71E9E47F8"><enum>(3)</enum><text display-inline="yes-display-inline">In the case of a report submitted by the
			 Commissioner of the Food and Drug Administration, a description of any
			 enforcement actions taken for violations of section 301(jj) of the Federal
			 Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331(jj)</external-xref>), including—</text>
				<subparagraph id="H6550666D5AC4493EA45C80C076E254CF"><enum>(A)</enum><text>warning letters or
			 fines imposed related to reporting requirements; and</text>
				</subparagraph><subparagraph id="H8FF141AEF2614DE393F8FEFA273B5D6F"><enum>(B)</enum><text>any inquiries made
			 to responsible parties to inform those parties of any potential enforcement
			 action.</text>
				</subparagraph></paragraph><paragraph id="HEA452371496640FC991FBC23805EDFDE"><enum>(4)</enum><text display-inline="yes-display-inline">In the case of a report submitted by the
			 Director of the National Institutes of Health, a description of any actions
			 taken to withhold grant funds from responsible parties that are not compliant
			 with the requirements of this section as indicated in 402(j)(5)(A) of the
			 Public Health Service Act.</text>
			</paragraph></section><section id="H452AEF4FD2D54D1EA84D533FFAD0AB50"><enum>4.</enum><header>Rulemaking
			 related to foreign clinical studies</header>
			<subsection id="H4DCD4838D7AE45F58FE83A63AAB545DA"><enum>(a)</enum><header>Drugs</header><text display-inline="yes-display-inline">Not later than 1 year after the date of
			 enactment of this Act, the Secretary of Health and Human Services shall issue
			 final regulations to amend <external-xref legal-doc="usc" parsable-cite="usc/21/312">section 312.120</external-xref> of title 21, Code of Federal
			 Regulations (relating to foreign clinical studies not conducted under an IND)
			 to require that clinical trial information for such a foreign clinical study be
			 submitted for inclusion in the registry and results data bank in accordance
			 with section 402(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>), as
			 amended by this Act, as a condition for the acceptance of such study as support
			 for an IND (as such term is defined in <external-xref legal-doc="usc" parsable-cite="usc/21/312">section 312.3</external-xref> of title 21, Code of
			 Federal Regulations) or application for marketing approval (an application
			 under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>)
			 or section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>)).</text>
			</subsection><subsection id="HDE53B4E48EFE496FB9C2E97D357F9110"><enum>(b)</enum><header>Devices</header><text display-inline="yes-display-inline">Not later than 1 year after the date of
			 enactment of this Act, the Secretary of Health and Human Services shall issue
			 final regulations (including regulations amending <external-xref legal-doc="usc" parsable-cite="usc/21/814">section 814.15</external-xref> of title 21,
			 Code of Federal Regulations (relating to research conducted outside the United
			 States)) to require that clinical trial information for studies conducted
			 outside the United States be submitted for inclusion in the registry and
			 results data bank in accordance with section 402(j) of the Public Health
			 Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>), as amended by this Act, as a condition for the
			 acceptance of such studies to support a PMA (as such term is defined in section
			 814.3(e) of title 21, Code of Federal Regulations), a premarket notification
			 required under section 510(k) of the Federal Food, Drug, and Cosmetic Act (21
			 U.S.C. 360(k)), or HDE (as such term is defined in section 814.3(m) of title
			 21, Code of Federal Regulations).</text>
			</subsection></section></legis-body>
</bill>


